Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

95.61USD
23 Feb 2018
Change (% chg)

$1.83 (+1.95%)
Prev Close
$93.78
Open
$94.10
Day's High
$95.66
Day's Low
$93.96
Volume
1,654,469
Avg. Vol
2,738,386
52-wk High
$147.13
52-wk Low
$88.34

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition

* CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​ Source text for Eikon: Further company coverage:

21 Feb 2018

BRIEF-Amunix Operating Says Has Entered Into A Licensing Agreement With Celgene

* AMUNIX OPERATING SAYS HAS ENTERED INTO A LICENSING AGREEMENT WITH CELGENE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

20 Feb 2018

BRIEF-Celularity Announces Formation Of Co With $250 Mln In Funding From Celgene, United Therapeutics, Others

* ‍CELULARITY ANNOUNCES $250 MILLION IN FUNDING TO DELIVER TREATMENTS FOR CANCER, INFLAMMATORY AND DEGENERATIVE DISEASES, AND FUNCTIONAL REGENERATION​

15 Feb 2018

BRIEF-Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients

* OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS

15 Feb 2018

BRIEF-Celgene Corp Elects John Weiland To Its Board

* CELGENE CORPORATION ELECTS JOHN WEILAND TO ITS BOARD OF DIRECTORS

15 Feb 2018

BRIEF-Celgene Announces Additional $5 Billion Share Repurchase Authorization

* CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION

14 Feb 2018

BRIEF-Celgene Prices $4.5 Billion Of Senior Unsecured Notes

* CELGENE CORP - ANNOUNCED PRICING OF FOUR SERIES OF SENIOR UNSECURED NOTES

09 Feb 2018

BRIEF-Celgene Corp Announces Positive Results From The Pivotal Phase III ‘Optimismm’ Study Of Pomalyst/Imnovid

* CELGENE CORPORATION ANNOUNCES POSITIVE RESULTS FROM THE PIVOTAL PHASE III ‘OPTIMISMM’ STUDY OF POMALYST/IMNOVID® FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA

06 Feb 2018

BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics

* CELGENE CORPORATION COMMENCES TENDER OFFER FOR JUNO THERAPEUTICS, INC.

02 Feb 2018

BRIEF-Celgene Says Entered Into Settlement With Actavis​

* CELGENE - ENTERED INTO SETTLEMENT WITH ACTAVIS LLC TO TERMINATE PENDING PATENT LITIGATION, IPR CHALLENGES RELATING TO CERTAIN PATENTS FOR ABRAXANE​

26 Jan 2018

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,956 +70.00
Eisai Co., Ltd (4523.T) ¥5,631 +61.00
Johnson & Johnson (JNJ.N) $132.02 +2.11
Novartis AG (NOVN.S) CHF79.38 -0.60
Pfizer Inc. (PFE.N) $36.26 +0.52
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Sanofi SA (SASY.PA) €65.05 +0.16
AstraZeneca plc (AZN.L) 4,752.00 -20.00

Earnings vs. Estimates